Status:
RECRUITING
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Urothelial Carcinoma
Renal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be sele...
Eligibility Criteria
Inclusion
- 1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
- 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
- 3\. Age ≥ 18 years
- 4\. Patient affiliated to a French Social Security scheme
- 5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.
Exclusion
- 1\. Patient with localized disease.
- 2\. Pregnant or breast-feeding women.
- 3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
- 4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Key Trial Info
Start Date :
July 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 23 2029
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06967961
Start Date
July 23 2025
End Date
July 23 2029
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncopole Claudius Regaud, IUCT-O
Toulouse, France, 31059